28 Multiple Myeloma Clinical Trials in Denver, CO (2026)

Q: How do I join a clinical trial in Denver?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you.

Recruiting Multiple Myeloma Studies in Denver

NCT07656584Recruiting

Implementation of Communication Disability Collection and Accommodations in Primary Care Settings

This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disa...

Denver, CONA126,870 participantsNYU Langone Health

View Study Details

NCT05243797Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclista...

Denver, COPHASE31,594 participantsStichting European Myeloma Network

View Study Details

NCT04638647Recruiting

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment w...

Denver, COPHASE41,000 participantsNovartis Pharmaceuticals

View Study Details

NCT07095452Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...

Denver, COPHASE2660 participantsAbbVie

View Study Details

NCT06892522Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Denver, COPHASE1602 participantsAbbVie

View Study Details

NCT07266831Recruiting

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to ...

Denver, COPHASE2570 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07391657Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethaso...

Denver, COPHASE3508 participantsAstraZeneca

View Study Details

NCT07258511Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody....

Denver, COPHASE3400 participantsJanssen Research & Development, LLC

View Study Details

NCT04787042Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatme...

Denver, COPHASE1316 participantsSimcha IL-18, Inc.

View Study Details

NCT02343042Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...

Denver, COPHASE1300 participantsKaryopharm Therapeutics Inc

View Study Details

NCT05231629Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is mu...

Denver, COPHASE2300 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06455449Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease a...

Denver, COPHASE3240 participantsAstraZeneca

View Study Details

NCT06297226Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma....

Denver, COPHASE2230 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06500884Recruiting

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...

Denver, COPHASE2210 participantsJanssen Research & Development, LLC

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Denver, COPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

Denver, COPHASE1182 participantsAstraZeneca

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

Denver, COPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT06722235Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...

Denver, COPHASE3171 participantsTakeda

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

Denver, COPHASE2157 participantsJanssen Research & Development, LLC

View Study Details

NCT06948318Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making i...

Denver, COPHASE3150 participantsTakeda

View Study Details

NCT05828511Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high d...

Denver, COPHASE1149 participantsRegeneron Pharmaceuticals

View Study Details

NCT06896916Recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease ac...

Denver, COPHASE1135 participantsAbbVie

View Study Details

NCT07409246Recruiting

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 ...

Denver, COPHASE1127 participantsAbbVie

View Study Details

NCT05972135Recruiting

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients...

Denver, COPHASE2100 participantsSCRI Development Innovations, LLC

View Study Details

NCT06974786Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary ob...

Denver, COPHASE2100 participantsSCRI Development Innovations, LLC

View Study Details

NCT05469893Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. Peop...

Denver, COPHASE252 participantsIrene Ghobrial, MD

View Study Details

NCT07073547Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM)....

Denver, COPHASE140 participantsAstraZeneca

View Study Details

NCT07146906Recruiting

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression....

Denver, COPHASE232 participantsNovartis Pharmaceuticals

View Study Details

About Multiple Myeloma Clinical Trials in Denver

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 28 multiple myeloma clinical trials recruiting participants in Denver, CO. These studies are seeking a combined 135,562 participants. Research is being sponsored by NYU Langone Health, Stichting European Myeloma Network, Novartis Pharmaceuticals and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Denver — FAQ

Are there multiple myeloma clinical trials in Denver?

Yes, there are 28 multiple myeloma clinical trials currently recruiting in Denver, CO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Denver?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.

Are clinical trials in Denver free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 28 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 22, 2026 from ClinicalTrials.gov